This study is testing KYN-5356, an oral tablet, to see if it can improve thinking and memory problems (cognitive impairment) in adults with schizophrenia. We are looking for 150 adults, aged 18 to 55, who have been diagnosed with schizophrenia for at least one year and are currently stable on their antipsychotic medication. Participants will receive either KYN-5356 at a low, medium, or high dose, or a placebo (an inactive tablet). The main goal is to see how well KYN-5356 works on cognitive function after 28 days. The study's current status is unclear.

Study design

This is a Phase 2 study with 150 participants. It is randomized, meaning you would be assigned to a treatment group by chance, and double-blind, meaning neither you nor the study team will know which treatment you are receiving.

What's involved

You would be admitted to a clinic for 32 days, staying there from 3 days before treatment starts until the end of the 28-day treatment period. During this time, you would take the study medication daily.

Compensation

Not stated in the trial record.

Follow-up

The main effects on cognitive function are measured at 28 days, which is the end of the treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.